All data are based on the daily closing price as of December 3, 2024
c

CHO Pharma

6586.TWO
1.57 USD
0.01
+0.64%

Overview

Last close
1.57 usd
Market cap
335.57M usd
52 week high
2.76 usd
52 week low
1.54 usd
Target price
N/A usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
10087.395
Price/Book Value
3.8243
Enterprise Value
262.81M usd
EV/Revenue
7898.7536
EV/EBITDA
-34.5511

Key financials

Revenue TTM
33271.83 usd
Gross Profit TTM
N/A usd
EBITDA TTM
-6.68M usd
Earnings per Share
-0.04 usd
Dividend
N/A usd
Total assets
3.01B usd
Net debt
-95.99M usd

About

CHO Pharma, Inc., a biopharmaceutical company, develops and commercializes therapeutic and diagnostic products for the unmet clinical needs. It is developing homogeneous antibody drugs, such as CHO-H01, CHO-H02, and CHO-A04, a humanized monoclonal antibody for cancer; CHO-H03, a homogeneous antibody drug for autoimmune diseases; CHO-S05 dual-effect anti-flu drugs; and CHO-V08 for Klebsiella pneumonia. The company was founded in 2012 and is based in Taipei City, Taiwan.
  • Symbol
    6586.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Dr. Chung-Yi Wu Ph.D.
  • Headquarter
    Taipei
  • Web site
    https://www.chopharma.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top